Leukemia & Lymphoma Society

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.

As Razorback nation’s medical campus, the University of Arkansas for Medical Sciences is a hub for medical treatment, research and academics. UAMS offers an impressive number of academic programs through its many divisions: * College of Medicine * College of Pharmacy * College of Nursing * College of Health Related Professions * College of Public Health * Graduate School As you can expect, a great number of programs are available through these schools and colleges. University of Arkansas for Medical Sciences offers undergraduate and graduate academics, ranging from certificates to master’s and doctoral degrees. With such exhaustive academics comes equally extensive research. Some research opportunities at University of Arkansas for Medical Sciences are more straightforward, while others are quite unusual. For example, students in the Psychiatric Research Institute were recently able to enrich college life by talking to actors in the Arkansas Repertory Theatre. Admissions requirements at University of Arkansas for Medical Sciences are very program-specific. The admissions process is handled through the individual college you’re applying to, so procedures and requirements may vary. This applies to financial aid, as well; so make sure to consult University of Arkansas for Medical Sciences for specific information.

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.

OncoPep, Inc. is a biopharmaceutical company focused on developing targeted immunotherapeutics for cancer treatment. Founded in 2010 and based in North Andover, Massachusetts, OncoPep specializes in creating cancer vaccines that stimulate the immune system to combat specific cancers. Its lead product, PVX-410, is a multi-peptide therapeutic vaccine aimed at treating smoldering multiple myeloma, a precursor to more advanced stages of the disease. The company’s proprietary technology, developed in collaboration with Dr. Kenneth Anderson at the Dana Farber Cancer Institute, utilizes a unique combination of peptides and adjuvants to enhance immune response against cancer cells. OncoPep is also exploring therapies for other malignancies, including triple-negative breast cancer and various solid tumors, with the goal of preventing disease progression and improving patient quality of life.

Epizyme, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing epigenetic medicines for cancer and other diseases. The company has achieved a significant milestone with its approved product, Tazemetostat, which is used for treating metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed and refractory follicular lymphoma and high-risk diffuse large B-cell lymphoma. Epizyme is also engaged in developing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, alongside inhibitors targeting PRMT5 and PRMT1 for solid tumors and blood cancers. The company collaborates with several industry leaders and research organizations to advance its innovative therapeutic programs, reflecting its commitment to translating epigenetic research into effective treatments. Founded in 2007, Epizyme aims to reshape cancer treatment through its focus on molecularly targeted drugs.